CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company is known for Barostim™, the first FDA-approved neuromodulation device for heart failure, which helps restore autonomic nervous system balance. This presentation offers investors insight into CVRx's innovative therapies and future prospects. A live webcast and archived presentation will be available on the company's investor relations website.
More than 15 pharmaceutical companies are actively developing over 20 drugs for synovial sarcoma, a rare and aggressive cancer. Key players like Takara Bio, Immatics, and ModernaTX are testing promising therapies in various clinical trial phases, inc...
U.S. stocks reached record highs with the S&P 500 up 0.5%, driven by strong gains in AI-related companies like Snowflake, which surged 37% after exceeding earnings and revenue expectations. The market optimism followed a 60-day ceasefire extension be...
Idea Grove, a Dallas-based B2B PR and AI visibility agency, published its 2026 Trust Signals® B2B Brand Rankings, highlighting top companies across 16 technology and industrial sectors such as cybersecurity, fintech, AI automation, and manufacturing....
CrowdStrike has formed a strategic collaboration with major insurers like Coalition, Liberty Mutual, and Lockton to develop a framework addressing financial risks from frontier AI in cybersecurity. The company also expanded its presence in Germany by...
Super Micro Computer's shares rose over 10% following news that the company is collaborating with Taiwanese authorities to prevent illegal export of its AI server technology. This move comes amid a smuggling investigation involving Nvidia chips embed...
